313. Cell Type Specific Media Optimization for Clinical Retroviral Transduction Protocols

In order to optimize the transduction of CD34+ cells, CD34+ derived Langerhans cells (LCs) and T lymphocytes for upcoming clinical trials, we determined which medium is best suited for each cell type. Our aim is to identify the formulation providing the best cell proliferation, survival and the highest transduction efficiency (TE) while maintaining the biological activity of the cells. To this end, we harvested and screened PG13-derived retroviral vector stocks (VS) collected in various media formulations. High-titer VS were consistently obtained by controlling PG13 cell-plating densities, time of cell growth and vector harvests. We also periodically determined the titer of the frozen VS to determine how long these VS can be stored for clinical applications.